Charles Theuer Biography and Net Worth
Dr. Theuer has served as our President, Chief Executive Officer and a member of our board of directors since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
What is Charles Theuer's net worth?
The estimated net worth of Charles Theuer is at least $574,461.42 as of January 18th, 2023. Dr. Theuer owns 339,918 shares of TRACON Pharmaceuticals stock worth more than $574,461 as of February 7th. This net worth approximation does not reflect any other assets that Dr. Theuer may own. Learn More about Charles Theuer's net worth.
What is Charles Theuer's salary?
As the CEO of TRACON Pharmaceuticals, Inc., Dr. Theuer earned a total compensation package of $2,059,112.00 in 2021. Dr. Theuer earned a salary of $584,637.00, options awards of $1,231,578.00, non-equity compensation of $231,297.00, and other compensation of $11,600.00. Learn More on Charles Theuer's salary.
How do I contact Charles Theuer?
Has Charles Theuer been buying or selling shares of TRACON Pharmaceuticals?
During the last ninety days, Charles Theuer has bought $11,016.00 of TRACON Pharmaceuticals stock. Most recently, on Wednesday, January 18th, Charles Theuer bought 6,800 shares of TRACON Pharmaceuticals stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $11,016.00. Following the completion of the transaction, the chief executive officer now directly owns 339,918 shares of the company's stock, valued at $550,667.16. Learn More on Charles Theuer's trading history.
Who are TRACON Pharmaceuticals' active insiders?
Are insiders buying or selling shares of TRACON Pharmaceuticals?
In the last twelve months, TRACON Pharmaceuticals insiders bought shares 33 times. They purchased a total of 1,260,082 shares worth more than $1,779,315.74. In the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 1,539 shares worth more than $2,216.16. The most recent insider tranaction occured on January, 18th when CEO Charles Theuer bought 6,800 shares worth more than $11,016.00. Insiders at TRACON Pharmaceuticals own 3.5% of the company. Learn More about insider trades at TRACON Pharmaceuticals.
Information on this page was last updated on 1/18/2023.
Charles Theuer Insider Trading History at TRACON Pharmaceuticals
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
TRACON Pharmaceuticals Company Overview
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
50 Day Range
2 Week Range